Small human pharmacology studies exist (healthy volunteers, 2006); development was discontinued — no approval
CJC-1295 with DAC was studied in healthy adults in single- and multiple-dose pharmacokinetic trials that reported injection-site reactions, headache, diarrhoea and flushing, with sustained GH and IGF-1 elevation for days after a dose. The compound never reached approval. Long-term safety of sustained GH elevation is the open question.
Research-use information only. Research-grade CJC-1295 is not an approved medicine; where trial or label figures appear below they belong to the pharmaceutical product studied, not to any research vial. This page does not give dosing or medical advice.
Every rate carries its source. Where no source exists, no rate is printed.
| Effect | Rate (sourced) | Detail | Source |
|---|---|---|---|
| Injection-site reactions, headache, diarrhoea, flushing | not quantified | Reported in the phase 1 programme; mostly mild and transient. | Teichman et al. 2006 |
| Sustained GH and IGF-1 elevation | not quantified | IGF-1 stayed elevated for up to 28 days after multiple doses — the pharmacology, and the reason long-term concerns exist. | Teichman et al. 2006 |
Regulatory status: Not approved anywhere; development discontinued in the late 2000s.
DAC extends the half-life to days, so GH/IGF-1 stay elevated continuously; no-DAC (Mod GRF 1-29) acts for minutes and produces a pulse. Continuous elevation is the profile with more theoretical long-term concern.